More than one-third of patients with oropharyngeal cancer were seropositive for HPV16 E6 an average of 6 years prior to their cancer diagnosis compared with less than 1% of healthy controls, a new study has found.
Older multiple myeloma patients exposed to novel agents prior to autologous peripheral blood stem cell transplantation were at increased risk for engraftment syndrome.
The phase II portion of the GAUGUIN study found promising activity with the anti-CD20 antibody obinutuzumab in patients with relapsed or refractory indolent NHL.
A phase I/II study found that radioimmunotherapy with 177Lu and the anti-CD20 antibody rituximab along with the chelator DOTA is safe and feasible for treatment of relapsed follicular, mantle cell, or other indolent lymphomas.
A large and prospective study shows that a high concentration of omega-3 fatty acids is linked to a higher risk of aggressive prostate cancer.
The results of two studies indicate that combining antibodies against the programmed death 1 (PD-1) receptor with an antibody against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) improved treatment outcomes for patients with advanced melanoma, without a significant increase in adverse events.
General practitioners took longer to suspect a diagnosis of bladder or renal cancer in women compared with men, according to a recent study.
Patients who received a prescription for a lethal dose of secobarbital as part of a Death with Dignity program qualitatively described being grateful for the prescription, whether or not it was used, according to a recent study.
A high skeletal muscle density has been linked to a twofold prolonged survival in patients with metastatic renal cell carcinoma compared with patients with low muscle density, according to a new study.
The FDA approved afatinib (Gilotrif) as a first-line therapy for patients with metastatic non-small-cell lung cancer whose tumors harbor certain mutations in the epidermal growth factor receptor gene.